Literature DB >> 15122789

Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization.

Angela Domínguez1, Miquel Bruguera, Pere Plans, Josep Costa, Lluís Salleras.   

Abstract

The objective of this study was to investigate the prevalence of hepatitis A antibodies (anti-HAV) in schoolchildren in Catalonia and to compare it with the rates found in previous studies. Sera from a representative sample of 1,342 children aged between 6 and 15 years, recruited in 2001, were tested for anti-HAV. The results were related to sociodemographic variables and vaccination history. The overall prevalence of anti-HAV was 51.4%. The prevalence was 5.5% in non-vaccinated children, similar to that found in a 1996 study, and 96.6% in vaccinated children. The prevalence of anti-HAV in non-vaccinated children increased significantly with age, reaching 11.6% in the 13-15 years age group. The prevalence of anti-HAV was higher in children born outside Catalonia than in those born in Catalonia (16.1% vs. 5.0%, P = 0.02). The expected continuation in the decline in the prevalence of anti-HAV in non-vaccinated schoolchildren, observed in Catalonia since 1986, was not found in 2001. The rate of anti-HAV in 2001 was slightly higher than in 1996, although the difference was not statistically significant (5.5 and 3.5%, respectively). This could be explained by the increased number of recent immigrant children born outside Catalonia, mainly in countries where hepatitis A is highly endemic. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122789     DOI: 10.1002/jmv.20072

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study.

Authors:  Filippo Ansaldi; Bianca Bruzzone; Maria Cristina Rota; Antonino Bella; Marta Ciofi degli Atti; Paolo Durando; Roberto Gasparini; Giancarlo Icardi
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

2.  Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey.

Authors:  Ahmet Soysal; Ibrahim Gokçe; Tamer Pehlivan; Mustafa Bakir
Journal:  Eur J Pediatr       Date:  2007-02-22       Impact factor: 3.183

3.  Marked decrease in the incidence and prevalence of hepatitis A in the Basque Country, Spain, 1986-2004.

Authors:  G Cilla; E Pérez-Trallero; J Artieda; E Serrano-Bengoechea; M Montes; D Vicente
Journal:  Epidemiol Infect       Date:  2006-07-19       Impact factor: 2.451

Review 4.  Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Authors:  Andrea M Anonychuk; Andrea C Tricco; Chris T Bauch; Ba' Pham; Vladimir Gilca; Bernard Duval; Ava John-Baptiste; Gloria Woo; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Hepatitis A virus genotype distribution during a decade of universal vaccination of preadolescents.

Authors:  Lucía D'Andrea; Francisco J Pérez-Rodríguez; Montserrat de Castellarnau; Sandra Manzanares; Josep Lite; Susana Guix; Albert Bosch; Rosa M Pintó
Journal:  Int J Mol Sci       Date:  2015-03-25       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.